SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards as the community discusses concerns around declining traffic, margin pressures, and lowered sales outlook, potentially driven by consumer spending habits and pricing. Some traders believe the stock is oversold, presenting a buying opportunity, while others express concerns about the company's current leadership and competitive landscape. Community members are also debating if a change in strategy is needed to better appeal to a broader customer base.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to renewed optimism fueled by raised FY25 EBITDA guidance and a potential short squeeze, with the community actively discussing target prices and the possibility of further upside. A top-line Q3 beat and recent earnings surprise are adding to the positive sentiment. Some traders are closely monitoring the stock's short interest and anticipating a significant price movement.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is seeing active discussion around its correlation to Bitcoin and upcoming earnings, with community members debating its valuation relative to its Bitcoin holdings and expressing concerns about potential downside. Some traders are closely watching options activity and speculating on potential catalysts, while others question the company's strategy and management. The stock's performance relative to Bitcoin's price movement remains a key talking point.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it will host an analyst and investor event focused on lacutamab, an asset with path...

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Szary Syndrome

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety...

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate...

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General...

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key...

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced new data highlighting the quality-of-life improvements observed in patients with...

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into...

Innate Pharma Releases Its 2025 Financial Calendar

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May...

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the publication in Science Immunology of preclinical data demonstrating the potential of...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$1.97
Prev Close	$2.07
Open	$2.04
Dividend Yield	0.00%
50-Day Moving Average	$2.05
Beta	0.34
Avg. Volume	21,030.29
PE Ratio	-3.47

52-Week High	$3.51
52-Week Low	$1.29
Market Capitalization	$159.48M
EPS (Annual)	-$0.6602
Price to Book	31.59
Revenue Per Employee	$75,431.50
Enterprise Value/EBITDA	N/A

IPHA
Innate Pharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IPHA News

IPHAInnate Pharma